In the annual congress of ESMO or European Society for Medical Oncology, in Madrid a study was presented by the researchers, wherein Xalkori was described as a wonder drug. This drug is manufactured by Pfizer Incorporation and is new in the market. It is mainly for the treatment of a rare type of lung cancer- the non small cell lung cancer. In a clinical trial, surprising effects of Xalkori are shown in reducing the size of the tumor. This treatment proves to be very effective for people suffering from this uncommon form of illness which has a relation to gene defect.
Dr. Alice Shaw, the lead investigator reported that this clinical trial is the first solid study which establishes crizotinib’s activity in victims of lung cancer who are tested positive for ROS1 and also confirms ROS1 as an authentic therapeutic target in such patients.
The study involved around 50 individuals who were diagnosed with NSCLC with a mutation in ROS1 gene. Out of the 50, shrinkage in tumor size was seen in 36 patients who consumed the drug. A remarkable conclusion was made that 72 percent of the people were benefitted from the Pfizer medication through reduction in fatal tumors. Moreover, if Xalkori is taken on a regular basis, the progression of the disease can be halted. This halt was noted in 9 patients.
In a separate statement, Dr. Shaw stated that the resistance with Xalkori develops quite later in comparison with other therapies used for the treatment of melanoma or lung cancer.